EXAS Stock - Exact Sciences Corporation
Unlock GoAI Insights for EXAS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.76B | $2.50B | $2.08B | $1.77B | $1.49B |
| Gross Profit | $1.92B | $1.76B | $1.42B | $1.31B | $1.14B |
| Gross Margin | 69.5% | 70.5% | 68.3% | 74.0% | 76.2% |
| Operating Income | $-1,048,703,000 | $-215,012,000 | $-593,511,000 | $-855,678,000 | $-767,696,000 |
| Net Income | $-1,028,857,000 | $-204,149,000 | $-623,506,000 | $-595,625,000 | $-823,605,000 |
| Net Margin | -37.3% | -8.2% | -29.9% | -33.7% | -55.2% |
| EPS | $-5.59 | $-1.13 | $-3.54 | $-3.48 | $-5.45 |
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Visit WebsiteEarnings History & Surprises
EXASEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 18, 2026 | — | — | — | — |
Q4 2025 | Nov 3, 2025 | $-0.06 | $0.24 | +492.0% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $-0.02 | $0.22 | +1200.0% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $-0.37 | $-0.21 | +43.2% | ✓ BEAT |
Q1 2025 | Feb 19, 2025 | $-0.29 | $-0.06 | +79.3% | ✓ BEAT |
Q4 2024 | Nov 5, 2024 | $-0.20 | $-0.21 | -7.2% | ✗ MISS |
Q3 2024 | Jul 31, 2024 | $-0.37 | $-0.09 | +75.7% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.47 | $-0.50 | -5.3% | ✗ MISS |
Q1 2024 | Feb 21, 2024 | $-0.53 | $-0.27 | +49.1% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $-0.48 | $0.00 | +100.9% | ✓ BEAT |
Q3 2023 | Aug 1, 2023 | $-0.50 | $-0.45 | +10.0% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.79 | $-0.42 | +46.8% | ✓ BEAT |
Q1 2023 | Feb 21, 2023 | $-0.90 | $-0.72 | +20.0% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-1.10 | $-0.84 | +23.6% | ✓ BEAT |
Q3 2022 | Aug 2, 2022 | $-1.07 | $-0.94 | +12.1% | ✓ BEAT |
Q2 2022 | Apr 26, 2022 | $-1.12 | $-1.04 | +7.1% | ✓ BEAT |
Q1 2022 | Feb 22, 2022 | $-0.91 | $-1.28 | -40.7% | ✗ MISS |
Q4 2021 | Nov 2, 2021 | $-0.89 | $-0.97 | -9.0% | ✗ MISS |
Q3 2021 | Jul 28, 2021 | $-0.72 | $-1.03 | -43.1% | ✗ MISS |
Latest News
Frequently Asked Questions about EXAS
What is EXAS's current stock price?
What is the analyst price target for EXAS?
What sector is Exact Sciences Corporation in?
What is EXAS's market cap?
Does EXAS pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to EXAS for comparison